(SBRA) Sabra Healthcare REIT - Overview
Sector: Real Estate | Industry: REIT - Healthcare Facilities | Exchange: NASDAQ (USA) | Market Cap: 5.225m USD | Total Return: 21% in 12m
Avg Turnover: 41.6M
Qual. Beats: 0
Rev. Trend: 96.3%
Qual. Beats: 0
Warnings
Altman Z'' -1.91 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Sabra Health Care REIT, Inc. is a Maryland-incorporated real estate investment trust that manages a diverse portfolio of healthcare-related properties across the United States and Canada. The company operates under a self-administered and self-managed structure, focusing on ownership and investment in facilities such as skilled nursing, senior housing, and behavioral health centers.
As a Health Care REIT, the company generates revenue primarily through long-term triple-net lease agreements, which shift responsibilities for taxes, insurance, and maintenance to the tenants. This sector often benefits from the demographic tailwinds of an aging population, though it remains sensitive to federal reimbursement policies and labor costs within the nursing industry.
Investors can evaluate the underlying asset quality and dividend sustainability of this REIT by reviewing the detailed metrics available on ValueRay.
- Occupancy recovery in skilled nursing facilities drives core revenue growth
- Medicare and Medicaid reimbursement rate changes impact operator lease coverage
- Elevated interest rates increase cost of debt and refinancing pressure
- Portfolio diversification into senior housing improves long-term cash flow stability
- Labor shortages at operator level constrain tenant rent payment capacity
| Net Income: 156.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.40 > 1.0 |
| NWC/Revenue: -26.26% < 20% (prev 6.00%; Δ -32.26% < -1%) |
| CFO/TA 0.07 > 3% & CFO 366.7m > Net Income 156.2m |
| Net Debt (2.59b) to EBITDA (438.1m): 5.91 < 3 |
| Current Ratio: 0.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (256.0m) vs 12m ago 6.52% < -2% |
| Gross Margin: 63.48% > 18% (prev 0.68%; Δ 6.28k% > 0.5%) |
| Asset Turnover: 15.02% > 50% (prev 13.76%; Δ 1.26% > 0%) |
| Interest Coverage Ratio: 2.08 > 6 (EBITDA TTM 438.1m / Interest Expense TTM 115.9m) |
| A: -0.04 (Total Current Assets 123.5m - Total Current Liabilities 336.9m) / Total Assets 5.59b |
| B: -0.37 (Retained Earnings -2.05b / Total Assets 5.59b) |
| C: 0.04 (EBIT TTM 241.5m / Avg Total Assets 5.41b) |
| D: -0.73 (Book Value of Equity -2.05b / Total Liabilities 2.80b) |
| Altman-Z'' = -1.91 = D |
As of June 02, 2026, the stock is trading at USD 19.05 with a total of 3,024,409 shares traded.
Over the past week, the price has changed by -3.96%,
over one month by -2.34%,
over three months by -1.92% and
over the past year by +21.04%.
Sabra Healthcare REIT has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy SBRA.
- StrongBuy: 5
- Buy: 1
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.7 | 19.1% |
P/E Trailing = 32.8889
P/E Forward = 32.1543
P/S = 6.4063
P/B = 1.8756
P/EG = 5.2841
Revenue TTM = 812.8m USD
EBIT TTM = 241.5m USD
EBITDA TTM = 438.1m USD
Long Term Debt = 2.31b USD (from longTermDebt, last quarter)
Short Term Debt = 8.92m USD (from shortTermDebt, last quarter)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter) + Leases 20.2m
Net Debt = 2.59b USD (calculated: Debt 2.71b - CCE 123.5m)
Enterprise Value = 7.81b USD (5.23b + Debt 2.71b - CCE 123.5m)
Interest Coverage Ratio = 2.08 (Ebit TTM 241.5m / Interest Expense TTM 115.9m)
EV/FCF = 21.45x (Enterprise Value 7.81b / FCF TTM 364.4m)
FCF Yield = 4.66% (FCF TTM 364.4m / Enterprise Value 7.81b)
FCF Margin = 44.82% (FCF TTM 364.4m / Revenue TTM 812.8m)
Net Margin = 19.21% (Net Income TTM 156.2m / Revenue TTM 812.8m)
Gross Margin = 63.48% ((Revenue TTM 812.8m - Cost of Revenue TTM 296.8m) / Revenue TTM)
Gross Margin QoQ = 61.38% (prev 62.05%)
Tobins Q-Ratio = 1.40 (Enterprise Value 7.81b / Total Assets 5.59b)
Interest Expense / Debt = 4.27% (Interest Expense 115.9m / Debt 2.71b)
Taxrate = 1.33% (526k / 39.4m)
NOPAT = 238.3m (EBIT 241.5m * (1 - 1.33%))
Current Ratio = 0.31 (Total Current Assets 123.5m / Total Current Liabilities 402.6m)
Debt / Equity = 0.97 (Debt 2.71b / totalStockholderEquity, last quarter 2.79b)
Debt / EBITDA = 5.91 (Net Debt 2.59b / EBITDA 438.1m)
Debt / FCF = 7.11 (Net Debt 2.59b / FCF TTM 364.4m)
Total Stockholder Equity = 2.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.89% (Net Income 156.2m / Total Assets 5.59b)
RoE = 3.23% (Net Income TTM 156.2m / Total Stockholder Equity 4.84b)
RoCE = 3.38% (EBIT 241.5m / Capital Employed (Equity 4.84b + L.T.Debt 2.31b))
RoIC = 4.36% (NOPAT 238.3m / Invested Capital 5.47b)
WACC = 5.00% (E(5.23b)/V(7.94b) * Re(5.40%) + D(2.71b)/V(7.94b) * Rd(4.27%) * (1-Tc(0.01)))
Discount Rate = 5.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 4.23%
[DCF] Terminal Value 77.79% ; FCFF base≈346.7m ; Y1≈393.4m ; Y5≈564.1m
[DCF] Fair Price = 23.47 (EV 8.51b - Net Debt 2.59b = Equity 5.92b / Shares 252.2m; r=8.35% [WACC [floored]]; 5y FCF grow 13.81% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 96.32 | Revenue CAGR: 13.64% | SUE: 0.74 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.17 | Chg30d=-4.74% | Revisions=-20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.17 | Chg30d=-5.56% | Revisions=-33% | Analysts=3
EPS current Year (2026-12-31): EPS=0.67 | Chg30d=-3.60% | Revisions=-20% | GrowthEPS=+11.0% | GrowthRev=+11.0%
EPS next Year (2027-12-31): EPS=0.74 | Chg30d=-5.31% | Revisions=-20% | GrowthEPS=+10.9% | GrowthRev=+12.7%
[Analyst] Revisions Ratio: -33%